Related Experiment Video

Updated: Jul 28, 2025

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells
10:28

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Published on: January 10, 2018

8.4K

macroH2A2 antagonizes epigenetic programs of stemness in glioblastoma

Ana Nikolic1,2,3, Francesca Maule1,2, Anna Bobyn1,2,4

  • 1Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.

Nature Communications
|May 27, 2023
PubMed

Insights

Histone variant macroH2A2 regulates glioblastoma cell self-renewal by controlling chromatin accessibility. High macroH2A2 levels correlate with better prognosis in glioma patients, offering a potential therapeutic target.

Area of Science:

  • Molecular Biology
  • Cancer Epigenetics
  • Glioblastoma Research

Background:

  • Self-renewal is a key glioblastoma (GBM) cell property, driven by chromatin regulators and transcription factors.
  • Targeting epigenetic mechanisms of GBM self-renewal is crucial for developing effective treatments for this lethal cancer.

Purpose of the Study:

  • To identify and characterize a novel epigenetic axis regulating GBM self-renewal.
  • To investigate the role of the histone variant macroH2A2 in GBM self-renewal and therapeutic sensitivity.

Main Methods:

  • Utilized omics assays (genomics, transcriptomics) and functional assays.
  • Employed patient-derived in vitro and in vivo glioblastoma models.
  • Analyzed clinical cohorts to correlate macroH2A2 levels with patient prognosis.

Main Results:

  • macroH2A2 shapes chromatin accessibility at enhancer elements, antagonizing GBM self-renewal transcriptional programs.
  • macroH2A2 sensitizes glioblastoma cells to cell death through a viral mimicry response.
  • High macroH2A2 expression in clinical cohorts is associated with improved high-grade glioma patient prognosis.

Conclusions:

  • macroH2A2 represents a targetable epigenetic regulator of glioblastoma self-renewal.
  • macroH2A2 may serve as a prognostic biomarker for high-grade glioma.
  • Targeting the macroH2A2-mediated epigenetic axis offers potential new therapeutic strategies for glioblastoma.

More Related Videos

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections05:45

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

9.7K
Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

5.7K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
3.1K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K